<p>NRx Pharmaceuticals（纳斯达克代码：NRXP - 获取免费报告）于周五公布了季度财报。公司报告的每股收益为（$0.18），低于分析师一致预期的（$0.11），差距为（$0.07），据 Zacks 报道。公司本季度的收入为 24 万美元，而分析师预期为 683 万美元。</p>
<p>获取 <strong>NRx Pharmaceuticals</strong> 警报：</p>
<h2>NRx Pharmaceuticals 股票下跌 3.9%</h2>
<p>周五，纳斯达克：NRXP 的股票交易下跌 0.10 美元，报 2.49 美元。该股票的交易量为 432,261 股，而其平均交易量为 475,505 股。NRx Pharmaceuticals 的 12 个月低点为 1.13 美元，12 个月高点为 6.01 美元。该股票的 50 日简单移动平均为 3.02 美元，200 日简单移动平均为 2.87 美元。该股票的市值为 4933 万美元，市盈率为-1.11，贝塔值为 1.76。</p>
<h2>机构投资者对 NRx Pharmaceuticals 的看法</h2>
<p>对冲基金最近买卖了该股票的股份。Two Sigma Investments LP 在第三季度将其在 NRx Pharmaceuticals 的持仓增加了 66.4%。Two Sigma Investments LP 现在拥有 52,332 股该公司的股票，价值 173,000 美元，此前在该期间内增持了 20,880 股。Geode Capital Management LLC 在第二季度将其在 NRx Pharmaceuticals 的股份增加了 27.9%。Geode Capital Management LLC 现在拥有 172,255 股该公司的股票，价值 562,000 美元，此前在上个季度增持了 37,598 股。最后，Vanguard Group Inc.在第三季度将其在 NRx Pharmaceuticals 的股份增加了 18.3%。Vanguard Group Inc.现在拥有 534,956 股该公司的股票，价值 1,765,000 美元，此前在上个季度增持了 82,781 股。对冲基金和其他机构投资者持有该公司 4.27% 的股份。</p>
<h2>分析师评级上调和下调</h2>
<p>一些股票分析师最近对 NRXP 股票发表了评论。Weiss Ratings 在 10 月 8 日的报告中重申了对 NRx Pharmaceuticals 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 16 日的报告中重申了 “买入” 评级，并对 NRx Pharmaceuticals 股票设定了 40.00 美元的目标价。Wall Street Zen 在周六的报告中将 NRx Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Ascendiant Capital Markets 在 10 月 30 日的研究报告中将 NRx Pharmaceuticals 的股票目标价从 46.00 美元上调至 47.00 美元，并给予该公司 “买入” 评级。最后，D. Boral Capital 在 11 月 10 日的研究报告中重申了 “买入” 评级，并对 NRx Pharmaceuticals 的股票设定了 34.00 美元的目标价。四位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 34.75 美元。</p>
<p><strong>查看我们对 NRXP 的最新分析</strong></p>
<h2>关于 NRx Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>NRx Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，开发用于治疗中枢神经系统疾病的新型疗法，包括自杀性抑郁症、创伤后应激障碍和慢性疼痛。其产品包括 NRX-101（D-环丝氨酸/卢拉西酮），这是一种口服固定剂量的 D-环丝氨酸和卢拉西酮的组合，获得了食品和药物管理局指定的自杀治疗耐药性双相抑郁症的突破性疗法；以及 NRX-100（氯胺酮），该药物已获得 FDA 快速通道认证，用于治疗伴有急性自杀意念和行为的重度双相抑郁症。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 NRx Pharmaceuticals</li>
<li>交易暂停的解释</li>
<li>3 只低调的 AI 股票，值得在下跌时购买</li>
<li>什么是日经 225 指数？</li>
<li>你的感恩节投资计划：3 只将受益于足球热潮的股票</li>
<li>3 只值得长期持有的 REITs</li>
<li>MarketBeat 周回顾 – 11/10 - 11/14</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA"/></p>
<h2>你现在应该投资 NRx Pharmaceuticals 1000 美元吗？</h2>
<p>在你考虑 NRx Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 NRx Pharmaceuticals 并不在名单上。</p>
<p>虽然 NRx Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NRXP

<p>NRx Pharmaceuticals（纳斯达克代码：NRXP）报告了每股亏损 0.18 美元，低于市场普遍预期的 0.08 美元。该公司的收入为 24 万美元，低于预期的 683 万美元。股价下跌 3.9%，至 2.49 美元。机构投资者增加了持股，分析师的评级意见不一，市场共识目标价为 34.75 美元。NRx 专注于开发中枢神经系统疾病的治疗方案</p>

<p>NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.07), Zacks reports. The company had revenue of $0.24 million for the quarter, compared to analysts' expectations of $6.83 million.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals（纳斯达克代码：NRXP - 获取免费报告）于周五公布了季度财报。公司报告的每股收益为（$0.18），低于分析师一致预期的（$0.11），差距为（$0.07），据 Zacks 报道。公司本季度的收入为 24 万美元，而分析师预期为 683 万美元。</p>
</div><p>Get <strong>NRx Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>NRx Pharmaceuticals</strong> 警报：</p>
</div><h2>NRx Pharmaceuticals Stock Down 3.9%</h2>
<div class="lb-trans"><h2>NRx Pharmaceuticals 股票下跌 3.9%</h2>
</div><p>Shares of NASDAQ:NRXP traded down $0.10 during trading on Friday, hitting $2.49. The stock had a trading volume of 432,261 shares, compared to its average volume of 475,505. NRx Pharmaceuticals has a 12-month low of $1.13 and a 12-month high of $6.01. The stock has a 50-day simple moving average of $3.02 and a two-hundred day simple moving average of $2.87. The stock has a market capitalization of $49.33 million, a price-to-earnings ratio of -1.11 and a beta of 1.76.</p>
<div class="lb-trans"><p>周五，纳斯达克：NRXP 的股票交易下跌 0.10 美元，报 2.49 美元。该股票的交易量为 432,261 股，而其平均交易量为 475,505 股。NRx Pharmaceuticals 的 12 个月低点为 1.13 美元，12 个月高点为 6.01 美元。该股票的 50 日简单移动平均为 3.02 美元，200 日简单移动平均为 2.87 美元。该股票的市值为 4933 万美元，市盈率为-1.11，贝塔值为 1.76。</p>
</div><h2>Institutional Investors Weigh In On NRx Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 NRx Pharmaceuticals 的看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP raised its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company's stock worth $173,000 after acquiring an additional 20,880 shares during the period. Geode Capital Management LLC raised its position in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company's stock worth $562,000 after purchasing an additional 37,598 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company's stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近买卖了该股票的股份。Two Sigma Investments LP 在第三季度将其在 NRx Pharmaceuticals 的持仓增加了 66.4%。Two Sigma Investments LP 现在拥有 52,332 股该公司的股票，价值 173,000 美元，此前在该期间内增持了 20,880 股。Geode Capital Management LLC 在第二季度将其在 NRx Pharmaceuticals 的股份增加了 27.9%。Geode Capital Management LLC 现在拥有 172,255 股该公司的股票，价值 562,000 美元，此前在上个季度增持了 37,598 股。最后，Vanguard Group Inc.在第三季度将其在 NRx Pharmaceuticals 的股份增加了 18.3%。Vanguard Group Inc.现在拥有 534,956 股该公司的股票，价值 1,765,000 美元，此前在上个季度增持了 82,781 股。对冲基金和其他机构投资者持有该公司 4.27% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>A number of equities analysts recently commented on NRXP shares. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright restated a &#34;buy&#34; rating and issued a $40.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, October 16th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Ascendiant Capital Markets boosted their price objective on shares of NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 30th. Finally, D. Boral Capital restated a &#34;buy&#34; rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, November 10th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $34.75.</p>
<div class="lb-trans"><p>一些股票分析师最近对 NRXP 股票发表了评论。Weiss Ratings 在 10 月 8 日的报告中重申了对 NRx Pharmaceuticals 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 16 日的报告中重申了 “买入” 评级，并对 NRx Pharmaceuticals 股票设定了 40.00 美元的目标价。Wall Street Zen 在周六的报告中将 NRx Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Ascendiant Capital Markets 在 10 月 30 日的研究报告中将 NRx Pharmaceuticals 的股票目标价从 46.00 美元上调至 47.00 美元，并给予该公司 “买入” 评级。最后，D. Boral Capital 在 11 月 10 日的研究报告中重申了 “买入” 评级，并对 NRx Pharmaceuticals 的股票设定了 34.00 美元的目标价。四位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 34.75 美元。</p>
</div><p><strong>View Our Latest Analysis on NRXP</strong></p>
<div class="lb-trans"><p><strong>查看我们对 NRXP 的最新分析</strong></p>
</div><h2>About NRx Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 NRx Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.</p>
<div class="lb-trans"><p>NRx Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，开发用于治疗中枢神经系统疾病的新型疗法，包括自杀性抑郁症、创伤后应激障碍和慢性疼痛。其产品包括 NRX-101（D-环丝氨酸/卢拉西酮），这是一种口服固定剂量的 D-环丝氨酸和卢拉西酮的组合，获得了食品和药物管理局指定的自杀治疗耐药性双相抑郁症的突破性疗法；以及 NRX-100（氯胺酮），该药物已获得 FDA 快速通道认证，用于治疗伴有急性自杀意念和行为的重度双相抑郁症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than NRx Pharmaceuticals</li>
<li>Trading Halts Explained</li>
<li>3 Under-the-Radar AI Stocks to Buy on the Dip</li>
<li>What is the Nikkei 225 index?</li>
<li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>MarketBeat Week in Review – 11/10 - 11/14</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 NRx Pharmaceuticals</li>
<li>交易暂停的解释</li>
<li>3 只低调的 AI 股票，值得在下跌时购买</li>
<li>什么是日经 225 指数？</li>
<li>你的感恩节投资计划：3 只将受益于足球热潮的股票</li>
<li>3 只值得长期持有的 REITs</li>
<li>MarketBeat 周回顾 – 11/10 - 11/14</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlJYUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=NRXP"/></p>
<h2>Should You Invest $1,000 in NRx Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 NRx Pharmaceuticals 1000 美元吗？</h2>
</div><p>Before you consider NRx Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 NRx Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NRx Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 NRx Pharmaceuticals 并不在名单上。</p>
</div><p>While NRx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 NRx Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NRx Pharmaceuticals（NASDAQ:NRXP）公布财报结果